bioMérieux – Increased outlook for full-year 2020
bioMérieux (Paris:BIM), a world leader in the field of in vitro
diagnostics, today released its adjusted outlook for full-year
- Full-year 2020 net sales are now expected to be around 18%
at constant exchange rates and scope of consolidation and
contributive operating income before non-recurring items about €600
- As a reminder, this 2020 exceptional performance is not
projectable beyond 2020
Fourth-quarter 2020 sales and 2020
February 24, 2021
Notes and definitions
The above forward-looking statements are based, entirely or
partially, on assessments or judgments that may change or be
modified, due to uncertainties and risks related to the Company’s
economic, financial, regulatory and competitive environment,
notably those described in the 2019 Universal Registration
Document. Accordingly, the Company cannot give any assurance nor
make any representation as to whether the objectives will be met.
The Company does not undertake to update or otherwise revise any
forecasts or objectives presented herein, except in compliance with
the disclosure obligations applicable to companies whose shares are
listed on a stock exchange.
Currency effect: this is
established by converting actual numbers at the average rates of
year y-1. In practice, those rates are either average rates
communicated by the ECB, or hedged rates if hedging instruments
have been set up.
Changes in scope of consolidation:
these are determined:
- for acquisitions in the period, by deducting from sales for the
period the amount of sales generated during the period by acquired
entities as from the date they entered the consolidated reporting
- for acquisitions in the previous period, by deducting from
sales for the period the amount of sales generated in the months in
the previous period during which the acquired entities were not
- for disposals in the period, by adding to sales for the period
the amount of sales generated by entities sold during the previous
period in the months of the current period during which these
entities were no longer consolidated;
- for disposals in the previous period, by adding to sales for
the period the amount of sales generated during the previous period
by the entities sold.
A world leader in the field of in vitro diagnostics for over 55
years, bioMérieux is present in 44 countries and serves more than
160 countries with the support of a large network of distributors.
In 2019, revenues reached €2.7 billion, with over 90% of sales
outside of France.
bioMérieux provides diagnostic solutions (systems, reagents,
software and services) which determine the source of disease and
contamination to improve patient health and ensure consumer safety.
Its products are mainly used for diagnosing infectious diseases.
They are also used for detecting microorganisms in agri-food,
pharmaceutical and cosmetic products.
bioMérieux is listed on the Euronext Paris stock market. Symbol:
BIM – ISIN Code: FR0013280286 Reuters: BIOX.PA/Bloomberg:
Corporate website: www.biomerieux.com
Note: Unless otherwise stated,
growth is expressed year-on-year at constant exchange rates and
scope of consolidation (like-for-like).
version on businesswire.com: https://www.businesswire.com/news/home/20201214005725/en/
Investor Relations bioMérieux Franck Admant Tel.:
+33 (0)4 78 87 20 00 firstname.lastname@example.org
Media Relations bioMérieux Olivier Rescaniere
Tel.: +33 (0)4 78 87 20 00 email@example.com
Image Sept Laurence Heilbronn Tel.: +33 (0)1 53 70 74 64
Claire Doligez Tel.: +33 (0)1 53 70 74 48 firstname.lastname@example.org